AKBA vs AMGN: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. AKBA and AMGN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined AKBA and AMGN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Akebia Therapeutics is a commercial-stage biopharmaceutical company built around treating kidney disease. Its flagship product is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor approved in the US to treat anemia caused by chronic kidney disease (CKD) in adults on dialysis. Vafseo launched in the US in January 2025 and is the company's primary growth engine. Akebia's second marketed product is Auryxia (ferric citrate), used to control serum phosphorus in dialysis patients and to treat iron deficiency anemia in non-dialysis CKD patients.

Full AKBA guide

Amgen (AMGN) is one of the world's largest biotechnology companies, developing, manufacturing, and selling human therapeutics primarily for serious illnesses. Its portfolio spans inflammation, oncology, cardiovascular disease, bone health, and rare diseases, with well-known products that have included Enbrel, Prolia and Xgeva, Repatha, Otezla, and a growing pipeline. Amgen pioneered large-scale recombinant-protein and antibody manufacturing and is a leader in biosimilars as older biologics lose patent protection. The 2023 acquisition of Horizon Therapeutics added rare-disease drugs such as Tepezza and Krystexxa. Amgen is also developing obesity and metabolic candidates, including investigational drugs in the GLP-1 class of weight-loss therapies. Headquartered in Thousand Oaks, California, and founded in 1980, Amgen is a member of the Dow Jones Industrial Average and returns substantial cash to shareholders through a growing dividend and buybacks.

Full AMGN guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• AKBA drivers: Vafseo launch trajectory; Dialysis channel and reimbursement.
• AMGN drivers: Rare disease and Horizon assets; Obesity and metabolic pipeline.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The dominant risk is concentration: Akebia is a small-cap biopharma whose fortunes rest heavily on a single product launch, so any slowdown in Vafseo uptake, reimbursement, or competition from injectable ESAs and rival HIF-PH inhibitors could quickly reset the thesis. For AMGN, amgen faces patent cliffs as older blockbusters lose exclusivity, exposing them to biosimilar competition and pricing pressure.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick AKBA if you believe its drivers more; AMGN if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the AKBA and AMGN guides.

AKBA. Figures are approximate and tied to the asOf date; verify live numbers before acting. For a small commercial-stage biopharma, traditional earnings multiples are of limited use because the company is in an investment phase and profitability depends on how fast Vafseo scales relative to spending. Investors typically watch product revenue trends, patient and prescriber counts, cash runway, and pipeline readouts more than a single P/E figure.

AMGN. Amgen trades at a moderate multiple typical of a mature large-cap biopharma, reflecting steady cash flow and a meaningful dividend balanced against patent-cliff and drug-pricing risk. The valuation embeds expectations for the rare-disease and obesity pipelines to offset declines in older franchises. All figures are approximate and move with the share price and reported results; verify current numbers before relying on them.

Headline figures (approximate, Jul 2026): AKBA shows revenue (ttm) roughly $230 to $240 million (trailing twelve months as of late 2025), q1 2026 total net product revenue about $52 million (Vafseo ~$15.8M, Auryxia ~$36.2M), vafseo growth patients treated up roughly 60% versus the prior quarter; net revenue growing sequentially, auryxia trend declining, with generic competition expanding in 2026 and revenue guided lower year over year; AMGN shows revenue (ttm) ~$33-35 billion (approximate, verify), operating margin ~30%+ (approximate, verify), p/e (ttm) ~20-25x (GAAP varies; approximate, verify), dividend yield ~3% (approximate, verify).

AKBA and AMGN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined AKBA and AMGN exposure against your real portfolio. It is not an investment adviser.